U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
The approval by the European Commission was based on positive results from two Phase III clinical trials, ELEVATE-TN in patients with previously untreated CLL and ASCEND in patients with relapsed or refractory CLL.
This is great news for CLL patients in Europe. It is already approved in several countries including the USA.
For more details see the official press release.
Related posts